Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01073943
First received: February 22, 2010
Last updated: October 23, 2012
Last verified: October 2012
Results First Received: August 10, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Treatment
Condition: Bowel Preparation
Interventions: Drug: PicoPrep
Drug: HalfLytely
Drug: bisacodyl

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
PicoPrep "Day Before" method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy
HalfLytely HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.

Participant Flow:   Overall Study
    PicoPrep     HalfLytely  
STARTED     300     303  
Safety Population (Treated)     296     302  
Intent to Treat Population     294 [1]   300 [1]
COMPLETED     287     295  
NOT COMPLETED     13     8  
Withdrawal by Subject                 8                 2  
Protocol Violation                 2                 1  
Adverse Event                 1                 1  
Lost to Follow-up                 0                 2  
Power outage; colonoscopy not done                 1                 0  
Subject forgot                 0                 1  
Unable to return for follow-up                 0                 1  
Could not tolerate prep                 1                 0  
[1] Two treated participants did not have an efficacy assessment performed.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
PicoPrep "Day Before" method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy
HalfLytely HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
Total Total of all reporting groups

Baseline Measures
    PicoPrep     HalfLytely     Total  
Number of Participants  
[units: participants]
  296     302     598  
Age  
[units: years]
Mean ± Standard Deviation
  56.8  ± 9.66     56.2  ± 10.11     56.5  ± 9.89  
Gender  
[units: participants]
     
Female     192     189     381  
Male     104     113     217  
Ethnicity (NIH/OMB)  
[units: participants]
     
Hispanic or Latino     8     15     23  
Not Hispanic or Latino     288     287     575  
Unknown or Not Reported     0     0     0  
Race/Ethnicity, Customized  
[units: participants]
     
American Indian or Alaska Native     0     1     1  
Asian     0     1     1  
Native Hawaiian or Other Pacific Islander     0     0     0  
Black or African American     22     32     54  
White     274     268     542  
Other     0     0     0  
Body Mass Index  
[units: kg/m^2]
Mean ± Standard Deviation
  29.185  ± 5.3209     29.541  ± 6.1688     29.365  ± 5.7634  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded Gastroenterologist   [ Time Frame: Day 2 ]

2.  Secondary:   Percentage of Participants Classified as Successes (Excellent, Good and Fair Ratings) For Ascending Colon Cleansing According to the Ottawa Scale As Assessed by a Blinded Gastroenterologist   [ Time Frame: Day 2 ]

3.  Secondary:   Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: How Easy or Difficult Was It To Consume the Study Drug?   [ Time Frame: Day 2 ]

4.  Secondary:   Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Were You Able to Consume the Entire Prep As Instructed?   [ Time Frame: Day 2 ]

5.  Secondary:   Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Please Describe Your Overall Experience With the Study Preparation   [ Time Frame: Day 2 ]

6.  Secondary:   Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: The Taste of This Study Preparation Was   [ Time Frame: Day 2 ]

7.  Secondary:   Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Ask Your Doctor for This Preparation Again if You Need Another Colonoscopy in the Future?   [ Time Frame: Day 2 ]

8.  Secondary:   Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Refuse the Same Preparation Again if it Were to be Prescribed to You in the Future?   [ Time Frame: Day 2 ]

9.  Secondary:   Participants With Treatment-Emergent Adverse Events (TEAEs)   [ Time Frame: up to one month ]

10.  Other Pre-specified:   Percentage of Participants Classified as Successes (Excellent, Good and Fair Ratings) For Colon Cleansing According to the Ottawa Scale As Assessed by a Blinded Gastroenterologist   [ Time Frame: Day 2 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame Treatment-emergent AEs occurring from Day 1 up to one month.
Additional Description No text entered.

Reporting Groups
  Description
PicoPrep "Day Before" method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy
HalfLytely HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.

Serious Adverse Events
    PicoPrep     HalfLytely  
Total, serious adverse events      
# participants affected / at risk     2/296 (0.68%)     1/302 (0.33%)  
Cardiac disorders      
Acute coronary syndrome † 1    
# participants affected / at risk     1/296 (0.34%)     0/302 (0.00%)  
Gastrointestinal disorders      
Ileus † 1    
# participants affected / at risk     0/296 (0.00%)     1/302 (0.33%)  
Injury, poisoning and procedural complications      
Anastomatic complication † 1    
# participants affected / at risk     1/296 (0.34%)     0/302 (0.00%)  
Metabolism and nutrition disorders      
Dehydration † 1    
# participants affected / at risk     1/296 (0.34%)     0/302 (0.00%)  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)      
Colon cancer † 1    
# participants affected / at risk     1/296 (0.34%)     0/302 (0.00%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (13.0)




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information